An observational study in Crohn Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-19.
Sponsored by Merck Sharp & Dohme LLC · Observational
This is an observational study to determine the prevalence of moderate to severe Crohn's disease (CD) among patients with active CD and to evaluate existing therapeutic trends in a standard clinical practice.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 71 is below the median of 162 across 608 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with diagnosed active Crohn's Disease who are inadequately controlled with their current therapy
Must be inadequately controlled with their current therapy and for whom physician
decides to switch treatment.
Exclusion Criteria
All participants enrolled
Drug: Physician standard-of-care
Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
Percentage of Crohn's disease participants among the study population with a Crohn's Disease Activity Index (CDAI) score of 220-450 at the enrollment to the study.
Time frame: Week 0
Record of treatment strategy followed
Time frame: Week 0 to 2 years
Change in the CDAI score during the observational period
Time frame: Week 0 to 2 years
Number of surgeries and hospitalizations during the observational period
Time frame: Week 0 to 2 years
No study locations are listed for this record.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC